Alterity Therapeutics
Business Services · Australia · 1-10 Employees
View Company Info for Free
Overview
Headquarters
350 Collins St L 14 Ste 4, Melbourne, Vi...Phone Number
+61 393494906Website
www.alteritytherapeutics.comRevenue
<$5 MillionStock Symbol
ATHIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
2
2
1
1
1
About Alterity Therapeutics
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to intercede in disease processes. The Company is based in Melbourne, Australia, and San Francisco, California, USA.Explore more
Alterity Therapeutics Org Chart
EG
Senior Director, CMC
LG
Senior Director CMC
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alterity Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alterity Therapeutics launches new products
Funding: Get notified immidiatlly once Alterity Therapeutics has new funding data
Congratulate Masked Content for being promoted to Masked Content at Alterity Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Alterity Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Alterity Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Alterity Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check out if Alterity Therapeutics is spiking on competitors!
Earning: See what the market has to say on Alterity Therapeutics recently announced quarterly report
Recommended Actions
Find VP level buyers at Alterity Therapeutics
Find more new buyers
Compare Similar Companies to Alterity Therapeutics
Compare insights from companies similar to Alterity Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Alterity Therapeutics
<$5M
1-10
Public
$48M
1997
TS
Tara SperanzaHead of Investor Relations & Communications
Company Profile Activity
Activity Insights
Alterity Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Alterity Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Alterity Therapeutics.
Alterity Therapeutics financials insights
Gather financial insights about Alterity Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Share Placement
$10M
2025
Share Placement
$25M
Stock/Share Issuance
$13M
Alterity Therapeutics Tech Stack
A closer look at the technologies used by Alterity Therapeutics
Most Recent Scoops
Funding
Funding
Funding
Funding
Event
Person-Based
David Stamler, Chief Executive Officer, has appeared on a podcast called "FEAR & GREED | Business News" on 12/16/2024. Topics discussed include Developing treatments, Parkinson's, Multiple System Atrophy.
Events, Podcast
New Hire
Executive Move
Executive Moves, New Hire
Alterity Therapeutics News & Media
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
– Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol —Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
– Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration –Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
– Alterity’s novel imaging and biomarker approach positions the Company at the forefront of clinical research in MSA –Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) –
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Alterity Therapeutics
Sign Up For FreeTo access detailed company insights
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical compounds to interc... Read More
